Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2024 08:00 ET
|
Replimune Group Inc
-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response...
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 17:00 ET
|
Replimune Group Inc
WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic...
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
May 16, 2024 08:00 ET
|
Replimune Group Inc
Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma expected Q2 2024 Recent Type C CMC...
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
April 07, 2024 17:00 ET
|
Replimune Group Inc
SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
March 26, 2024 07:30 ET
|
Replimune Group Inc
Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1...
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
March 06, 2024 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...
Replimune to Present at Three Upcoming Investor Conferences
March 05, 2024 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
February 08, 2024 08:00 ET
|
Replimune Group Inc
Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma demonstrating durability of responseCentrally reviewed 12-month...
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...